Strategic Wealth Partners Ltd. Has $805,000 Stock Position in Abbott Laboratories (NYSE:ABT)

Strategic Wealth Partners Ltd. reduced its stake in Abbott Laboratories (NYSE:ABT) by 1.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,116 shares of the healthcare product maker’s stock after selling 95 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Abbott Laboratories were worth $805,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABT. Regent Peak Wealth Advisors LLC raised its position in shares of Abbott Laboratories by 2.0% during the fourth quarter. Regent Peak Wealth Advisors LLC now owns 4,873 shares of the healthcare product maker’s stock worth $551,000 after purchasing an additional 97 shares during the period. Tallon Kerry Patrick acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $200,000. Capital & Planning LLC raised its position in shares of Abbott Laboratories by 1.2% during the fourth quarter. Capital & Planning LLC now owns 8,673 shares of the healthcare product maker’s stock worth $981,000 after purchasing an additional 100 shares during the period. Merit Financial Group LLC raised its position in shares of Abbott Laboratories by 17.0% during the fourth quarter. Merit Financial Group LLC now owns 50,340 shares of the healthcare product maker’s stock worth $5,694,000 after purchasing an additional 7,316 shares during the period. Finally, Sax Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $640,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 1.1%

ABT stock opened at $134.79 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a market capitalization of $234.51 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The stock has a fifty day moving average of $129.36 and a 200-day moving average of $124.17.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th were paid a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.75%. Abbott Laboratories’s dividend payout ratio is currently 30.61%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the sale, the senior vice president now owns 31,970 shares of the company’s stock, valued at $4,417,294.90. This trade represents a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sally E. Blount sold 2,600 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total value of $337,116.00. Following the transaction, the director now directly owns 34,058 shares in the company, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 95,278 shares of company stock valued at $12,745,859 in the last 90 days. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. UBS Group increased their price target on Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Bank of America increased their price target on Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Stifel Nicolaus increased their price target on Abbott Laboratories from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, April 17th. Raymond James increased their price target on Abbott Laboratories from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Thursday, April 17th. Finally, StockNews.com lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $142.59.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.